

Northumbria Research Link

Citation: Panagiotou, Marios, Johnson, Martin, Louvaris, Zafeiris, Baker, Julien, Church, Alistair, Peacock, Andrew and Vogiatzis, Ioannis (2017) A study of clinical and physiological relations of daily physical activity in precapillary pulmonary hypertension. *Journal of Applied Physiology*, 123 (4). pp. 851-859. ISSN 8750-7587

Published by: American Physiological Society

URL: <https://doi.org/10.1152/jappphysiol.00986.2016>
<<https://doi.org/10.1152/jappphysiol.00986.2016>>

This version was downloaded from Northumbria Research Link: <http://nrl.northumbria.ac.uk/31371/>

Northumbria University has developed Northumbria Research Link (NRL) to enable users to access the University's research output. Copyright © and moral rights for items on NRL are retained by the individual author(s) and/or other copyright owners. Single copies of full items can be reproduced, displayed or performed, and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata page. The content must not be changed in any way. Full items must not be sold commercially in any format or medium without formal permission of the copyright holder. The full policy is available online: <http://nrl.northumbria.ac.uk/policies.html>

This document may differ from the final, published version of the research and has been made available online in accordance with publisher policies. To read and/or cite from the published version of the research, please visit the publisher's website (a subscription may be required.)



UniversityLibrary



Northumbria
University
NEWCASTLE

1 Title: **A study of clinical and physiological relations of daily physical activity in**
2 **precapillary pulmonary hypertension.**

3

4 **Authors:** Marios Panagiotou¹, Martin K. Johnson¹, Zafeiris Louvaris^{2,3}, Julien S.
5 Baker⁴, Alistair C. Church¹, Andrew J. Peacock¹, Ioannis Vogiatzis^{2,5}.

6 **Author contributions:** MP obtained all of the data in the study, performed data
7 analysis and wrote the manuscript. ZL performed accelerometry data analysis. MP, MKJ,
8 ZL, JSB, ACH, AJP and IV contributed substantially to the study design, data
9 interpretation, and editing of the manuscript.

10 **Affiliations:** ¹Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital,
11 Glasgow, UK; ²Faculty of Physical Education and Sports Sciences, National and
12 Kapodistrian University of Athens, Athens, Greece; ³Faculty of Kinesiology and
13 Rehabilitation Sciences, Department of Rehabilitation Sciences KU Leuven, Division of
14 Respiratory Rehabilitation, University Hospitals Leuven, Belgium; ⁴Institute of Clinical
15 Exercise and Health Sciences, University of the West of Scotland, Hamilton, UK;
16 ⁵School of Health and Life Sciences, Northumbria University Newcastle, Newcastle
17 Upon-Tyne, UK.

18 **Corresponding author:** Marios Panagiotou; Scottish Pulmonary Vascular Unit,
19 Golden Jubilee National Hospital, Agamemnon Street, Glasgow, G81 4DY, UK; +44 141
20 9515497; mariopanag@gmail.com.

21 **Abstract**

22 Daily physical activity becomes reduced in precapillary pulmonary hypertension (PH)
23 but the underlying mechanisms are inadequately explored. We sought to investigate
24 clinical and physiological relations of daily physical activity and profile differences
25 between less and more active patients with precapillary PH. A prospective, cross-
26 sectional study of 20 patients with precapillary PH who undertook a) a comprehensive
27 clinical assessment, b) a preliminary treadmill test, c) 7-day monitoring of daily walking
28 intensity with triaxial accelerometry and d) a personalized treadmill test corresponding to
29 the individual patient mean daily walking intensity with real-time physiological
30 measurements. Significant clinical correlations with individual patient mean walking
31 intensity ($1.71 \pm 0.27 \text{ m/s}^2$) were observed for log N-terminal pro-brain natriuretic peptide
32 (log-NTproBNP: $r = -.75$, $p < .001$), age ($r = -.70$, $p = .001$), transfer factor for carbon
33 monoxide %predicted ($r = .51$, $p = 0.022$) and 6-minute walk distance ($r = .50$, $p = .026$).
34 Significant physiological correlations were obtained for heart rate reserve ($r = .68$,
35 $p = .001$), quadriceps tissue oxygenation index (Q-StO₂: $r = .58$, $p = .008$), change in Q-StO₂
36 from rest ($r = .60$, $p = .006$) and ventilatory equivalent for oxygen uptake ($r = -.56$, $p = .013$).
37 Stepwise multiple regression analyses retained log-NTproBNP ($R^2 = 0.55$), heart rate
38 reserve ($R^2 = 0.44$) and Q-StO₂ ($R^2 = 0.13$) accounting for a significant variance in
39 individual walking intensity. Less active patients had greater physical activity-induced
40 cardiopulmonary impairment, worse quadriceps oxygenation profile and compromised
41 health-related quality of life compared to more active patients. These preliminary
42 findings suggest a significant relation between right ventricular and peripheral muscle
43 oxygenation status and reduced daily physical activity in precapillary PH. Further

44 research is warranted to unravel the physiological determinants, establish clinical
45 predictors, and identify beneficial interventions.

46 **New & Noteworthy**

47 Daily physical activity holds promise to be meaningful, patient-related outcome
48 measure in pulmonary hypertension. Herein, novel findings in a representative sample of
49 patients with precapillary pulmonary hypertension link reduced daily walking activity, as
50 measured by triaxial accelerometry with compromised right ventricular and pulmonary
51 vascular status, peripheral muscle oxygenation and health-related quality of life. Thus,
52 this study provides preliminary insight into the physiological mechanisms and clinical
53 predictors of daily physical activity in precapillary pulmonary hypertension.

54 **Keywords:** pulmonary arterial hypertension, daily physical activity, right ventricle,
55 skeletal muscle oxygenation.

56 **Introduction**

57 Precapillary pulmonary hypertension (PH) comprises primarily pulmonary arterial
58 hypertension (PAH; group 1) and chronic thromboembolic pulmonary hypertension
59 (CTEPH; group 4) and is characterised by progressive elevation of vascular resistance in
60 the precapillary pulmonary vasculature and right heart failure (13). Despite important
61 advances in the understanding and targeted therapy to date, the morbidity and mortality in
62 precapillary PH remain high: typically, patients suffer progressive dyspnoea, impaired
63 exercise capacity and health-related quality of life (HRQoL), and premature death (1, 13,
64 37).

65 Physical activity is defined as the bodily movement produced by the contraction of
66 skeletal muscle that increases energy expenditure above the basal level and can be
67 described by dimensions of intensity, frequency, duration, mode and context (14). Daily
68 physical activity is an important dimension of HRQoL in cardiopulmonary disease (10,
69 43) and satisfies the core requirement of a meaningful patient-centered endpoint in
70 clinical trials, defined to be a direct measure of how a patient “feels, functions or
71 survives” where “function” refers to the ability to carry out normal daily activities (15).
72 Accordingly, enhancement of daily physical activity is recommended in PH (13);
73 however, research shows significantly reduced daily physical activity in patients with
74 precapillary PH compared to healthy controls and poorer survival in more sedentary
75 patients (21, 36, 39, 45).

76 The causes of reduced daily physical activity in PH are not adequately explored. Our
77 perception on the underlying mechanisms remains intuitively focused on pulmonary
78 vasculopathy and right ventricular dysfunction and limited to extrapolations from

79 standardized exercise testing (40), which may not correspond well to daily physical
80 activity (28, 47). Importantly, the role of peripheral muscles has not been investigated.
81 This is despite growing evidence on skeletal muscle abnormalities in PAH (31) and
82 recent findings suggesting that estimates of skeletal muscle oxygenation may reflect the
83 pathophysiology of PAH (32, 33). Importantly, the surrogate value of common clinical
84 tools in precapillary PH in the prediction of daily physical activity is not well established.

85 The purpose of this study was therefore to explore the physiological mechanisms and
86 predictors of reduced physical activity in precapillary PH. To this aim, we investigated
87 relations of patient daily walking intensity as measured by accelerometry with a) routine
88 clinical measures and b) cardiopulmonary and peripheral muscle physiological responses
89 during laboratory exercise corresponding to individual daily walking intensities. We also
90 explored profile differences between less and more active patients. We hypothesized that
91 along with pulmonary vasculature and right ventricular status, peripheral muscle function
92 might be a pertinent factor to reduce daily physical activity in precapillary PH.

93 **Materials & Methods**

94 Study Sample

95 Consecutive patients with stable PAH and technically non-operable (distal) CTEPH
96 who attended the Scottish Pulmonary Vascular Unit between November 2014 and
97 October 2015 were eligible. The diagnosis had been previously established by right heart
98 catheterisation as recommended (13). Clinical stability was defined as a) no
99 hospitalization for precapillary PH and b) no escalation in therapy for PH or diuretics
100 within 3 months. Exclusion criteria were pulmonary endarterectomy or comorbidities

101 interfering with physical activity and treadmill testing. Approval from the West of
102 Scotland Research Ethics Committee (14/WS/1075) and written consent were obtained.

103 Initial evaluation

104 Subjects had determination of WHO functional class, maximum voluntary ventilation
105 ($MVV = FEV_1 \times 35$) (1) and transfer factor for carbon monoxide (TLCO) corrected for
106 haemoglobin concentration. (19). They also completed the patient-reported Cambridge
107 Pulmonary Hypertension Outcome Review (CAMPHOR) (25) and emPHasis-10 (48),
108 two well-validated questionnaires for the assessment of HRQoL in PH. CAMPHOR is
109 probably the most widely studied questionnaire in PH and has been shown to predict
110 clinical deterioration in idiopathic PAH and CTEPH (24). However, neither CAMPHOR
111 nor emPHasis-10 questionnaires have been validated against objective, accelerometry
112 measures of daily physical activity to date.

113 Finally, N-terminal pro-brain natriuretic peptide (NTproBNP) and 6-minute walk
114 distance (6MWD) were retrieved from the medical record (median interval: 30 days for
115 both).

116 Preliminary treadmill test

117 Subjects performed an incremental treadmill test (RAM 770M; RAM Medical and
118 Industrial Instruments & Supplies, Padova, Italy) at an initial speed of 1.4 km/h that
119 increased by 0.8 km/h every 3 minutes to the limit of tolerance as previously described
120 (17, 18). The treadmill speed was determined by a communicating ergospirometry testing
121 system (CASE ES, GE Healthcare, Freiburg, Germany). Minute-by-minute walking
122 intensity was measured concurrently in units of acceleration (m/s^2) using a triaxial

123 activity monitor (DynaPort MoveMonitor; McRoberts, Netherlands). In this manner, a
124 range of intensities was obtained at various speeds and a graph of walking intensity
125 against treadmill speed was plotted for each patient. This was used to calculate a
126 treadmill speed corresponding to each patient's mean daily walking intensity, as
127 described below.

128 Accelerometry

129 Subjects were fitted with DynaPort accelerometers attached to an elastic strap and
130 positioned over L2 vertebra (an approximation of body's center of mass) to record their
131 daily walking intensity continuously for 7 days, excluding sleep and water-based
132 activities. Measurements were considered sufficient if technically acceptable signal was
133 obtained daily for a minimum of 12 consecutive hours, during 5 consecutive days (18,
134 34).

135 The DynaPort is a validated accelerometer that provides reliable measures of physical
136 activity including postures, steps and movement intensities even under sedentary
137 conditions (5, 37, 46). The intensity with which a person carries out activities of daily
138 living is a fundamental part of recommendations for health maintenance (14) and an
139 important aspect of the overall physical activity (17, 18).

140 Personalized treadmill test

141 Within 2 weeks, patients underwent a final, three-stage treadmill protocol during
142 which they sequentially: a) stood still on treadmill, b) warmed up at a speed of 1.4 km/h,
143 and c) walked at a predetermined treadmill speed corresponding to their individual daily
144 walking intensity (calculated by using the data from the preliminary test and monitoring

145 of daily walking intensity). The duration of each stage was 4 minutes in order to reach
146 steady physiological state (18). Continuous physiological measurements were obtained
147 throughout as described below. The resting and exercise value for each variable was the
148 average value obtained during the last minute of the first and third stage, respectively.

149 Metabolic profile

150 Oxygen uptake (VO_2), minute ventilation (V_E) and ventilatory equivalent ratio for
151 oxygen uptake (V_E/VO_2) and carbon dioxide (V_E/VCO_2) were recorded breath-by-breath
152 (CASE ES, GE Healthcare, Freiburg, Germany). Oxyhaemoglobin saturation (SpO_2) was
153 recorded continuously by pulse oximetry (OxywatchTM MD300C63, Beijing Choice
154 Electronic Tech. Co. Ltd, China). Electrocardiography was used to calculate heart rate
155 (HR) reserve (HRR) defined as the difference between age-predicted maximal HR (220 -
156 age) and peak HR (1).

157 Central hemodynamics

158 Estimates of stroke volume and cardiac output were measured using impedance
159 cardiography technology (PhysioFlow[®], Manatec Biomedical, France). PhysioFlow uses
160 variations in the transthoracic impedance to a high-frequency (75 kHz), low-amperage
161 (1.8 mA) alternating current across the thorax during cardiac ejection to calculate stroke
162 volume (4) and it has been previously validated (42) and used in PAH (12). Application
163 of six transthoracic electrodes, autocalibration, verification of signal quality and artifact
164 detection were performed as instructed by the manufacturer and described elsewhere (4).

165 Quadriceps oxygenation

166 Quadriceps tissue oxygenation index (Q-StO_2), as an expression of the local

167 microvascular oxygenation status, was measured using spatially resolved near infrared
168 spectroscopy (NIRO-200NX[®], Hamamatsu Photonics KK, Japan). Tissue oxygenation
169 index is essentially the ratio of oxygenated to total tissue hemoglobin concentration
170 expressed as $[\text{oxyhaemoglobin}/(\text{oxyhaemoglobin} + \text{deoxyhaemoglobin})] \times 100$ (%) and
171 represents an index of the dynamic balance between local tissue oxygen delivery and
172 utilisation in health and disease (3, 23). We have previously shown strong correlations
173 between Q-StO₂ and mixed venous oxygen saturation measured at pulmonary artery in
174 PAH subjects, both at rest and exercise (32, 33).

175 To measure Q-StO₂, one transcutaneous probe (S-type) housed in a black rubber
176 holder and fixed using a double-sided adhesive tape, was placed on the belly of each
177 vastus lateralis muscle, 10-12 cm above the lateral epicondyle. The values shown for Q-
178 StO₂ are the average from both legs. Estimated systemic oxygen delivery was calculated
179 as the product of cardiac output and arterial oxygen content; the latter was calculated as
180 the product of $1.34 \times \text{hemoglobin concentration} \times \%SpO_2$. The systemic arteriovenous
181 oxygen content difference (a-vO₂ difference) was calculated by dividing oxygen uptake
182 by cardiac output (Fick principle) whereas the systemic oxygen extraction ratio was
183 calculated as the ratio of the a-vO₂ difference to arterial oxygen content (18).

184 **Statistical analysis**

185 Data are reported as means \pm SD or median with 95% confidence interval of median.
186 NTproBNP was log-transformed due to positive skewing. Associations of mean daily
187 walking intensity were examined using the Pearson's correlation coefficient. Significant
188 parameters were further tested using stepwise multiple regression analysis. Patients were

189 dichotomised using the median daily walking intensity for an unpaired group comparison
190 using the Mann-Whitney *U*-test. Data were analyzed using the SPSS statistical package
191 (v 20, SPSS Inc., Chicago, IL). The level of significance was set at $p < .05$. On the basis of
192 data from a previous study (18), the critical sample size to achieve a power of 80% for
193 detection of differences between patient groups with two-sided level of significance $< .05$
194 was 16 patients (calculated using the Stata package; StataCorp LP, Texas, USA).

195 **Results**

196 Patient characteristics

197 Patients characteristics are presented in Table 1. Twenty patients enrolled, completed
198 the protocol without adverse effects and included in the analysis (Figure 1). Stroke
199 volume profile of 3 (15%) patients had to be excluded due to invalid impedance
200 cardiography signal. Sixteen patients had PAH (9, idiopathic PAH; 6, connective tissue
201 disease associated-PAH; 1, PAH after correction of congenital heart disease) and 4
202 patients had CTEPH. None of the patients had significant cardiac shunt detected at right
203 heart catheterisation or follow-up echocardiograms. All patients were on PH-specific
204 therapy: 10, monotherapy (7, phosphodiesterase-5 inhibitor (PDEi); 2, stimulator of
205 soluble guanylate cyclase (sGC); 1, endothelin receptor antagonist (ERA)) and 10,
206 combination therapy (6, PDE-i+ERA; 1, ERA+sGC; 3, PDEi+ERA+inhaled prostanoid).
207 None of the patients was on heart rate-limiting medication.

208 Total and daily time of accelerometry monitoring were 6.4 ± 0.94 days and 864 ± 94
209 min, respectively. Mean and median daily walking intensity were 1.71 ± 0.27 m/s² and
210 1.78 (1.55, 1.83) m/s², respectively. Daily walking time was 61 ± 26 min and daily steps
211 4897 ± 2209 .

212 Correlations and predictors of daily walking intensity

213 Significant clinical correlations with mean daily walking intensity were observed for
 214 log-NTproBNP ($r=-.75$, $p<.001$), age ($r=-.70$, $p=.001$) and 6MWD ($r=.50$, $p=.026$)
 215 (Table 1; Figure 2). Significant physiological correlations with mean daily walking
 216 intensity were observed for HRR ($r=.68$, $p=.001$), Q-StO₂, ($r=.58$, $p=.008$), change in Q-
 217 StO₂ from rest to mean daily walking intensity ($r=.60$, $p=.006$), V_E/VO₂ ($r=-.56$, $p=.013$)
 218 and TLCO %predicted ($r=.51$, $p=0.022$) (Table 2; Figure 2). There was no association
 219 between estimates of stroke volume at rest or exercise and mean daily walking intensity

220 Stepwise multivariate regression analysis of significant clinical measures retained log-
 221 NTproBNP ($b=-.290\pm.068$, $\beta=-.554$, $p=.001$) and age ($b=-.008\pm.002$, $\beta=-.486$, $p=.002$)
 222 accounting for 55% and 20% of the variance in mean daily walking intensity,
 223 respectively. Repeated for the significant physiological measures, analysis retained HRR
 224 ($b=.006\pm.002$, $\beta=.506$, $p=.015$) and Q-StO₂ at activity ($b=.01\pm.005$, $\beta=.395$, $p=.049$)
 225 accounting for 44% and 13% of the variance in mean daily walking intensity,
 226 respectively.

227 Comparison between less and more active patients

228 There was no significant difference in VO₂ between less and more active patients.
 229 Less active patients had significantly increased age, log-NTproBNP, V_E/MVV, V_E/VO₂,
 230 CAMPHOR and emPHasis-10 scores and decreased TLCO %predicted, HRR, Q-StO₂ at
 231 mean daily walking intensity and Q-ΔStO₂; they also showed 100-meter reduction in
 232 6MWD compared to more active patients (for all numerical values and P-values see
 233 Table 1 and 2).

234

235 **Discussion**

236 This exploratory study in a representative cohort with precapillary PH, reports on
237 significant associations of indices of right ventricular (log-NTproBNP, HRR) and
238 pulmonary vascular (TLCO %predicted) status with mean daily walking intensity. In
239 exercise conditions reproducing individual daily physical activity levels, measures of
240 quadriceps oxygenation (Q-StO₂ at activity, ΔQ-StO₂) and ventilatory efficiency
241 (V_E/VO₂) were also associated significantly with mean daily walking intensity. log-
242 NTproBNP, HRR and Q-StO₂ at mean activity levels predicted a significant variance in
243 mean daily walking intensity. Finally, the profile of less active patients comprised greater
244 cardiorespiratory impairment, worse quadriceps oxygenation profile and compromised
245 HRQoL compared to more active patients.

246 Walking intensity is an important aspect that a patient with lung disease adopts in
247 daily living. For example, numerous studies (Watz et al ERJ 2014; 44(6): 1521-1537)
248 have emphasized the finding that the intensity of movement adopted by COPD patients
249 during walking is reduced by an average of 17 to 33% compared to healthy age-matched
250 individuals. Daily walking intensity in the present cohort (1.7 m/s²) favorably compares
251 with that adopted by older patients with moderate/severe COPD (spirometric classes
252 II/III), typically corresponding to 1.8 m/s² (18, 34). Overall, the present population
253 adopted a sedentary (most commonly) or low-active lifestyle defined as daily steps of
254 <5000 and between 5000-7500, respectively (43). This adds to previous evidence (21, 36,
255 39, 45) on reduced measures of daily physical activity in precapillary PH.

256 The hemodynamic profile in precapillary PH depends mostly on the right ventricular

257 performance (16). NT-proBNP, a nonspecific marker of myocardial dysfunction, is
258 considered an indicator of the right ventricular status and a prognostic marker at
259 diagnosis and during follow-up in precapillary PH (13). Out of 35 variables, NT-proBNP
260 was also the strongest predictor of peak VO_2 and a significant predictor of 6MWD in
261 patients with chronic heart failure (11). In line, we observed a strong negative correlation
262 between log-NTproBNP and mean daily walking intensity whereas log-NTproBNP
263 predicted more than half of the variance in mean daily walking intensity and it was
264 significantly higher in less active patients.

265 Heart rate profiles in precapillary PH are thought to reflect the burden of the right
266 ventricle (16). In the setting of right ventricular failure and ensuing fixed/reduced stroke
267 volume, patients with precapillary PH become dependent on compensatory increase in
268 HR responses to maintain or increase cardiac output and preserve tissue oxygenation (16).
269 Hence, the HR- VO_2 relationship in precapillary PH is left-shifted with submaximal HR
270 values trending higher than normal (1). Accordingly, chronotropic response (peak
271 walking HR minus resting HR) and resting HR in PAH, have been independently
272 associated with 6MWD (35) and prognosis (16), respectively. Here, we extend these
273 findings by showing a strong relation between HRR and mean daily walking intensity
274 and significantly reduced HRR in less active

275 patients compared to more active patients. HRR also predicted almost half of the
276 variance in individual mean daily walking intensity.

277 The higher HR accounted for the higher cardiac output in less active patients in the
278 present study; estimates of stroke volume did not differ between less and more active

279 patients and it was dissociated with daily walking activity. Cardiac output as such also
280 did not correlate with daily walking intensity in the present cohort. Previous studies using
281 right heart catheterisation data also failed to show correlation between cardiac
282 output/index and daily physical activity levels in precapillary PH (21, 36). In contrast,
283 TLCO %predicted, reflecting pulmonary capillary volume, was also negatively
284 associated with mean daily walking intensity and 40% lower in less active patients.
285 Collectively, our findings on NT-proBNP and HRR profiles and, TLCO %predicted
286 speak for a significant relation between the right ventricular and pulmonary capillary
287 volume status and daily physical activity in precapillary PH.

288 The ventilatory response becomes exaggerated in precapillary PH due to
289 chemo/ergo/baro- receptor sensitivity, dead space ventilation and hypoxemic drive.
290 Premature lactic acidosis at the peripheral muscles due to hypoxemia will also increase
291 the ventilatory drive on activity. Physiologically, the ventilatory response to the
292 metabolic requirement is reflected in the V_E/VO_2 relationship (1). Accordingly, we
293 observed a negative correlation between V_E/VO_2 and mean daily walking intensity
294 whereas V_E/VO_2 and V_E/MVV were significantly higher among less active patients (by
295 almost 20% and 40%, respectively). V_E/VCO_2 , ratio, another important index of
296 ventilatory efficiency and of prognostic significance in precapillary PH, also differed
297 between the 2 groups (58 vs. 44); however, it did not reached statistical significance,
298 possibly, due to submaximal testing and small sample. Such an exaggerated ventilatory
299 response is highly relevant to physical activity as it may promote dyspnoea and cessation
300 of exercise.

301 Patients with PAH exhibit significant morphological and functional changes of

302 quadriceps muscle including alteration in the muscle fibre type, muscle atrophy, reduced
303 capillarity and oxidative capacity, and endothelial dysfunction (31). These abnormalities
304 may impair the local tissue oxygen delivery and utilization capacity, muscle strength and
305 exercise capacity (20). Importantly, muscle characteristics were unrelated to the
306 hemodynamic severity (20) and targeted exercise training reversed abnormalities and
307 improved exercise capacity (6, 26), which suggest that peripheral muscle abnormalities
308 may be implicated independently in the exercise pathophysiology of PAH. Here, Q-StO₂
309 at activity correlated with mean daily walking intensity, predicted a clinically significant
310 amount of the variance in daily walking intensity, and was significantly lower in less
311 active patients. Importantly, Δ Q-StO₂ responses opposed between patient groups: less
312 active patients drop Q-StO₂ whereas more active patients benefited from increased Q-
313 StO₂ at individual mean daily walking intensity.

314 Factors determining local muscle oxygenation are modulated by the rate of oxygen
315 delivery and oxygen extraction (8). Whereas arterial oxygen content and systemic oxygen
316 delivery did not differ between the present patient groups, less active patients had
317 significantly reduced a-vO₂ difference and ~ 10% reduction in oxygen extraction ratio
318 compared to more active patients. Collectively, our novel findings on estimates of muscle
319 oxygenation suggest a strong relation between capacity to enhance local muscle
320 oxygenation and better preserved daily physical activity and they provide support to the
321 peripheral muscle hypothesis (29). They also add to previous evidence showing: a)
322 impaired oxygen extraction rate during maximal exercise in PAH patients compared to
323 patients with pulmonary venous hypertension (41); b) lower thenar muscle resting StO₂ in
324 PAH compared to CHF and healthy subjects (9); c) greater quadriceps oxygen delivery-

325 to-utilization inequalities ($\Delta[\text{Mb-HHb}]$; change in deoxygenated myoglobin from rest to
326 exercise) in PAH compared to healthy subjects, which accounted for a slower rate of
327 adaptation of aerobic metabolism at exercise (2); and d) reduced quadriceps oxygenation
328 (lower $Q\text{-}\Delta\text{StO}_2$, higher $\Delta[\text{Mb-HHb}]$) in PAH compared to normal subjects even during
329 submaximal exercise (22); $\Delta[\text{Mb-HHb}]$ was also related to reduced quadriceps capillarity
330 and strength, and lower VO_2 (22).

331 Certainly, our study design does not allow for proof of causality and further research is
332 required before a primary impairment of peripheral muscle oxygenation is considered a
333 true limiting factor rather than a mere consequence of deconditioning, or reflection of
334 hypoxemia. Nonetheless, we found no association between $Q\text{-}\Delta\text{StO}_2$ and SpO_2 or arterial
335 oxygen content at rest/exercise ($p>0.5$ for all). Furthermore, $Q\text{-}\Delta\text{StO}_2$ and $\Delta[\text{Mb-HHb}]$ in
336 PAH subjects have been previously shown to remain unchanged with oxygen
337 supplementation (22).

338 A unified explanation may lie within the seemingly paradoxical absence of difference
339 in VO_2 between less and more active patients. It is possible that the metabolic
340 requirements of the increased workload (reduced HRR) of the stressed heart (increased
341 $\log\text{-NTproBNP}$) and increased/inefficient ventilation (increased V_E/MVV , V_E/VO_2) in
342 less active patients had matched the oxygen requirements of increased daily walking
343 intensity in more active patients. Teleologically, it may that both patient groups had
344 adjusted their activity to a certain threshold of oxygen/energy cost that allowed for
345 acceptable exertional symptoms such as muscle fatigue and breathlessness (as suggested
346 by responses in ventilation and estimates of quadriceps oxygenation). Ultimately, less
347 active patients showed convincingly compromised HQoL (worse CAMPHOR and

348 emPHasis-10 scores).

349 The current study is limited by its cross-sectional design, small sample and small
350 number of patients with advanced disease willing to undergo such a complex study
351 protocol. Stroke volume profile of 3 (15%) patients had to be excluded due to invalid
352 impedance cardiography signal but this limitation is inherent to impedance cardiography
353 and this figure is similar to previously published experience in precapillary PH (12).
354 Furthermore, the absence of direct measurement of peripheral muscle strength does not
355 allow for further exploration of the role of the peripheral muscle. Impedance
356 cardiography and Arterial oxygen content was estimated from using continuous SpO₂
357 readings at the expense of possible reduced accuracy in the hypoxaemic patients
358 compared to invasive arterial blood sampling. For patient comfort, measurements of
359 6MWD and NT-proBNP were retrospective in nature. However, we believe that in the
360 context of clinical stability (a prerequisite for patient inclusion in the study), an interval
361 of 30 days is an acceptable collection period for both measures. Finally, this study did not
362 investigate the possible impact of specific diseases and drug therapy on muscle function
363 or the effect of unmeasured variables such as environmental, social and personal factors
364 to daily physical activity. These factors might have accounted for the unexplained
365 variance in daily walking intensity and the moderate correlation of 6MWD with daily
366 walking intensity. Of note, neither CAMPHOR or emPHasis-10 scores correlated with
367 daily walking activity. Taken together with previously shown weak-to-moderate
368 correlations of accelerometry data with 6MWD and patient-reported questionnaire scores
369 (39), these findings question the surrogate value of routine clinical tools in the prediction
370 of daily physical activity in precapillary PH.

371

372

373 **Conclusions**

374 Daily physical activity holds promise to be meaningful, patient-related outcome
375 measure in PH. Our preliminary findings suggest a significant relation between right
376 ventricular and pulmonary vascular status, peripheral muscle oxygenation and HQoL
377 with reduced daily physical activity in precapillary PH. However, further research is
378 warranted to unravel the physiological determinants and establish the clinical predictors
379 of this phenomenon. The role of muscle function in the natural history of precapillary PH
380 merits particular focus as it offers a potential target for effective interventions.

381 **Acknowledgements**

382 We thank Val Pollock, Agnes Crozier, Karon Carson, Rachel Thomson, Kirsty
383 Menzies and Veronica Ferry for their contribution to patient recruitment and
384 administrative assistance.

385 **Disclosures**

386 Marios Panagiotou is the recipient of a European Respiratory Society PAH Long-
387 Term Research fellowship n° LTRF 2014-3106 supported by an unrestricted grant by
388 GSK. No conflicts exist for the rest of the authors.

389 **Figure Captions**

390 **Figure 1:** Study flow chart. BMI: body mass index; WHO FC: World Health
391 Organization functional class; TLCO: transfer factor for carbon monoxide; 6MWD: 6-
392 minute walk distance; log-NTproBNP: log-transformed N-terminal pro-brain natriuretic
393 peptide. VO_2 : oxygen uptake; V_E : minute ventilation; MVV: maximum voluntary
394 ventilation; V_E/VO_2 : ventilatory equivalent ratio for oxygen; V_E/VO_2 : ventilatory
395 equivalent ratio for carbon dioxide; SpO_2 : oxyhaemoglobin saturation; HRR: heart rate
396 reserve; SV: stroke volume; CO: cardiac output; Q-StO₂: quadriceps tissue oxygenation
397 index; Q- Δ StO₂: change in Q-StO₂ from rest to exercise. * Retrospective data (median
398 interval: 30 days); § Resting and exercise value was the average value obtained during the
399 last minute of the first and third stage, respectively; # SV/CO profile of 3 patients was
400 excluded due to invalid impedance cardiography signal.

401 **Figure 2:** Correlations (Pearson's r) between daily walking intensity recorded by
402 triaxial accelerometer and log N-terminal pro-brain natriuretic peptide (log-NTproBNP)
403 (A); age (B); heart rate reserve (HRR) (C); ventilatory equivalent ratio for oxygen uptake
404 (V_E/VO_2) (D); quadriceps tissue oxygenation index (Q-StO₂) at activity (E); and change
405 in Q-StO₂ from rest to activity (Q- Δ StO₂) (F) in 20 patients with precapillary pulmonary
406 hypertension.

407

408

409 **Table 1:** Clinical characteristics and comparison between less and more active patients¹

Variable	All (n=20)	Daily walking intensity, m/s^2		P-value
		< 1.78 (n=10)	≥ 1.78 (n=10)	
Walking Intensity, m/s^2	1.71 \pm 0.27	1.54 (1.29-1.75)	1.86 (1.79-2.03)	<.001*
Treadmill speed, km/hr	2.27 \pm .84	1.90 (1.00-2.90)	2.95 (1.80-3.20)	.037
Sex, m/f	8/12	4/6	4/6	N/A
Age, yr	54.1 \pm 15.9	66.0 (44.0-73.0)	48.5 (24.0-56.0)	.045*
BMI, kg/m^2	29.9 \pm 5.7	28.1 (18.8-31.6)	25.5 (21.3-29.7)	.705
Diagnosis				
Idiopathic PAH	9	4	5	N/A
CTD-PAH	6	4	2	N/A
CHD-PAH	1	0	1	N/A
CTEPH	4	2	2	N/A
WHO FC, I/II/III	4/12/4	1/5/4	3/7/0	N/A
mean PAP, $mm Hg$	45.1 \pm 13.3	46.0 (32.0-57.0)	40.0 (28.0-65.0)	.713

¹ Values are expressed as means \pm SD or median and 95% confidence interval of median. BMI: body mass index; PAH: pulmonary arterial hypertension; CTD-PAH: connective tissue disease associated PAH; CHD-PAH: PAH after correction of congenital heart disease; WHO FC: World Health Organization functional class; PAP, CO and PVR: historical pulmonary arterial pressure, cardiac output and pulmonary vascular resistance, respectively, measured at diagnostic right heart catheterization, prior to the initiation of PH-specific therapy; 6MWD: 6-minute walk distance; log-NTproBNP: log-transformed N-terminal pro-brain natriuretic peptide; TLCO: transfer factor for carbon monoxide. *Significant statistical difference between patient groups.

CO, <i>L/min</i>	3.8 ± 1.0	3.6 (2.6-4.3)	4.3 (3.3-5.0)	.102
PVR, <i>Wood units</i>	11.1 ± 5.7	12.3 (6.0-13.5)	8.7 (4.8-15.2)	.369
6MWD, <i>m</i>	418 ± 106	361 (298-513)	469 (347-570)	.076
CAMPHOR	23.2 ± 16.8	36.5 (8.0-46.0)	11.5 (0-36.0)	.041*
emPHasis-10	21.9 ± 14.1	31.0 (12.0-38.0)	13.5 (0-32.0)	.089
log-NTproBNP, <i>pg/mL</i>	2.53 ± 0.53	2.99 (2.75-3.29)	2.10 (1.79-2.42)	<.001*
FEV1, %pred.	89.9 ± 19.1	93.0 (80.0-115.5)	91.0 (65.8-98.5)	0.26
FVC, %pred.	112.4 ± 23.2	115.5 (100.3-141.5)	108.0 (90.0-122.3)	0.34
FEV1/FVC	66.5 ± 8.5	69.0 (60.3-72.0)	66.5 (63.3-71.0)	0.62

410 **Table 2:** Physiological characteristics and comparison between less and more active patients¹.

Variable	All (n=20)	Daily walking intensity, m/s^2		P-value
		< 1.78 (n=10)	\geq 1.78 (n=10)	
SpO ₂ activity, %	89.9 \pm 7.1	86.0 (81.0-95.0)	95.0 (88.0-96.0)	.1
HRR, <i>beats/min</i>	61.8 \pm 26.2	51.0 (9.0-57.0)	78.5 (67.0-91.0)	<.001*
SV rest/activity, <i>ml/beat</i>	66.5 \pm 21.5/ 80.9 \pm 21.6	59.2 (25.0-116.9)/ 74.1 (42.9-137.0)	63.6 (58.3-79.2)/ 78.9 (72.0-91.2)	.664/ .745
CO rest/activity, <i>l/min</i>	5.4 \pm 1.2 8.9 \pm 2.6	5.2 (3.3-7.1) 10.0 (6.8-16.1)	4.8 (4.2-6.7) 7.5 (6.8-9.3)	.495/ .045*
Q-StO ₂ rest/activity, %	64.1 \pm 7.4/ 65.4 \pm 10.6	63.7 (54.6-68.6)/ 60.5 (43.4-74.5)	65.7 (57.9-74.4)/ 71.4 (62.0-76.4)	.496/ .028*
Q- Δ StO ₂ , %	1.3 \pm 6.6	-2.3 (-6.0-1.8)	5.1 (3.2-7.8)	.003*
V _E /MVV, <i>l/min</i>	40.9 \pm 14.3	48.9 (32.2-60.0)	30.5 (25.9-39.6)	.007*
V _E /VO ₂	51.1 \pm 18.8	55.8 (39.8-81.1)	40.6 (34.3-58.2)	.041*
VO ₂ , <i>ml·kg⁻¹·min⁻¹</i>	9.5 \pm 1.4	9.4 (7.5-11.0)	9.7 (7.9-10.5)	.806
V _E /VCO ₂	52.1 \pm 13.6	57.7 (38.4-77.0)	44.0 (40.0-56.7)	.142
Arterial oxygen content,	18.1 \pm 1.42	17.3 (16.3-19.1)	19.1 (17.7-19.3)	.1

¹ Values are expressed as means \pm SD or median and 95% confidence interval of median. SpO₂: oxyhaemoglobin saturation; HRR: heart rate reserve; SV: stroke volume; CO: cardiac output; Q-StO₂: quadriceps tissue oxygenation index; Q- Δ StO₂: change in Q-StO₂ from rest to exercise; V_E: minute ventilation; MVV: maximum voluntary ventilation; V_E/VO₂: ventilatory equivalent ratio for oxygen; V_E/VCO₂: ventilatory equivalent ratio for carbon dioxide; VO₂: oxygen uptake; a-vO₂ difference: arterio-venous oxygen content difference. *Significant statistical difference between patient groups.

<i>ml/dl</i>				
Systemic oxygen delivery, <i>l/min</i>	1.4 ± .5	1.6 (1.1-2.6)	1.4 (1.2-1.6)	.556
Systemic a-vO ₂ difference difference, <i>mlO₂/100 ml</i>	7.7 ± 1.6	5.9 (5.1-8.3)	8.6 (6.7-9.8)	.017*
Systemic oxygen extraction, %	42 ± 11	35 (28-51)	44 (34-52)	.239

411 **References**

- 412
- 413 1. American Thoracic Society; American College of Chest Physicians. ATS/ACCP
414 Statement on cardiopulmonary exercise testing. *Am J Respir Crit Care Med* 167:
415 211-77, 2003.
- 416 2. Barbosa PB, Ferreira EM, Arakaki JS, Takara LS, Moura J, Nascimento RB, Nery
417 LE, Neder JA. Kinetics of skeletal muscle O₂ delivery and utilization at the onset
418 of heavy-intensity exercise in pulmonary arterial hypertension. *Eur J Appl
419 Physiol*; 111 :1851-61, 2011.
- 420 3. Boushel R, Langberg H, Olesen J, Gonzales-Alonzo J, Bülow J, Kjaer M.
421 Monitoring tissue oxygen availability with near infrared spectroscopy (NIRS) in
422 health and disease. *Scand J Med Sci Sports* 11: 213-22, 2001.
- 423 4. Charloux A, Lonsdorfer-Wolf E, Richard R, Lampert E, Oswald-Mammosser M,
424 Mettauer B, Geny B, Lonsdorfer J. A new impedance cardiograph device for the
425 non-invasive evaluation of cardiac output at rest and during exercise: comparison
426 with the "direct" Fick method. *Eur J Appl Physiol* 82: 313-20; 2000.
- 427 5. de Groot S, Nieuwenhuizen MG. Validity and reliability of measuring activities,
428 movement intensity and energy expenditure with the DynaPort MoveMonitor.
429 *Med Eng Phys* 35: 1499-505, 2013.
- 430 6. de Man FS, Handoko ML, Groepenhoff H, van 't Hul AJ, Abbink J, Koppers RJ,
431 Grotjohan HP, Twisk JW, Bogaard HJ, Boonstra A, Postmus PE, Westerhof N,
432 van der Laarse WJ, Vonk-Noordegraaf A. Effects of exercise training in patients
433 with idiopathic pulmonary arterial hypertension. *Eur Respir J* 34: 669-75, 2009.
- 434 7. Deboeck G, Niset G, Vachiery JL, Moraine JJ, Naeije R. Physiological response
435 to the six-minute walk test in pulmonary arterial hypertension. *Eur Respir J* 26:
436 667-72, 2005.
- 437 8. DeLorey DS, Kowalchuk JM, Paterson DH. Relationship between pulmonary O₂
438 uptake kinetics and muscle deoxygenation during moderate-intensity exercise. *J
439 Appl Physiol (1985)* 95: 113-20, 2003.
- 440 9. Dimopoulos S, Tzanis G, Manetos C, Tasoulis A, Mpouchla A, Tseliou E,
441 Vasileiadis I, Diakos N, Terrovitis J, Nanas S. Peripheral muscle microcirculatory
442 alterations in patients with pulmonary arterial hypertension: a pilot study. *Respir
443 Care* 58: 2134-41, 2013.
- 444 10. Esteban C, Quintana JM, Aburto M, Moraza J, Egurrola M, Pérez-Izquierdo J,
445 Aizpiri S, Aguirre U, Capelastegui A. Impact of changes in physical activity on
446 health-related quality of life among patients with COPD. *Eur Respir J* 36: 292-
447 300, 2010.
- 448 11. Felker GM, Whellan D, Kraus WE, Clare R, Zannad F, Donahue M, Adams K,
449 McKelvie R, Piña IL, O'Connor CM; HF-ACTION Investigators. N-terminal pro-
450 brain natriuretic peptide and exercise capacity in chronic heart failure: data from
451 the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise
452 Training (HF-ACTION) study. *Am Heart J* 158(4 Suppl): S37-44, 2009.
- 453 12. Ferreira EM, Ota-Arakaki JS, Barbosa PB, Siqueira AC, Bravo DM, Kapins CE,
454 Silva CM, Nery LE, Neder JA. Signal-morphology impedance cardiography

- 455 during incremental cardiopulmonary exercise testing in pulmonary arterial
456 hypertension. *Clin Physiol Funct Imaging* 32: 343-52, 2012.
- 457 13. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G,
458 Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA,
459 Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA,
460 Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the
461 diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the
462 Diagnosis and Treatment of Pulmonary Hypertension of the European Society of
463 Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by:
464 Association for European Paediatric and Congenital Cardiology (AEPC),
465 International Society for Heart and Lung Transplantation (ISHLT). *Eur Respir J*;
466 46: 903-75, 2015.
- 467 14. Global Recommendations on Physical Activity for Health. Geneva: World Health
468 Organization; 2010.
- 469 15. Gomberg-Maitland M, Bull TM, Saggari R, Barst RJ, Elgazayerly A, Fleming TR,
470 Grimminger F, Rainisio M, Stewart DJ, Stockbridge N, Ventura C, Ghofrani AH,
471 Rubin LJ. New trial designs and potential therapies for pulmonary artery
472 hypertension. *J Am Coll Cardiol* 62(25 Suppl): D82-91, 2013.
- 473 16. Henkens IR, Van Wolferen SA, Gan CT, Boonstra A, Swenne CA, Twisk JW,
474 Kamp O, van der Wall EE, Schalij MJ, Vonk-Noordegraaf A, Vliegen HW.
475 Relation of resting heart rate to prognosis in patients with idiopathic pulmonary
476 arterial hypertension. *Am J Cardiol* 103: 1451-6, 2009.
- 477 17. Kortianou EA, Louvaris Z, Vasilopoulou M, Nasis I, Kaltsakas G, Koulouris NG,
478 Vogiatzis I. Activity monitoring reflects cardiovascular and metabolic variations
479 in COPD patients across GOLD stages II to IV. *Respir Physiol Neurobiol* 189:
480 513-20, 2013.
- 481 18. Louvaris Z, Kortianou EA, Spetsioti S, Vasilopoulou M, Nasis I, Asimakos A,
482 Zakyntinos S, Vogiatzis I. Intensity of daily physical activity is associated with
483 central hemodynamic and leg muscle oxygen availability in COPD. *J Appl*
484 *Physiol* (1985) 115: 794-802, 2013.
- 485 19. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V,
486 Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R,
487 McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J.
488 Standardisation of the single-breath determination of carbon monoxide uptake in
489 the lung. *Eur Respir J* 26: 720-35, 2005.
- 490 20. Mainguy V, Maltais F, Saey D, Gagnon P, Martel S, Simon M, Provencher S.
491 Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension.
492 *Thorax* 65: 113-7, 2010.
- 493 21. Mainguy V, Provencher S, Maltais F, Malenfant S, Saey D. Assessment of daily
494 life physical activities in pulmonary arterial hypertension. *PLoS One* 6: e27993,
495 2011.
- 496 22. Malenfant S, Potus F, Mainguy V, Leblanc E, Malenfant M, Ribeiro F, Saey D,
497 Maltais F, Bonnet S, Provencher S. Impaired Skeletal Muscle Oxygenation and
498 Exercise Tolerance in Pulmonary Hypertension. *Med Sci Sports Exerc* 47: 2273-
499 82, 2015.

- 500 23. Mancini DM, Bolinger L, Li H, Kendrick K, Chance B, Wilson JR. Validation of
501 near-infrared spectroscopy in humans. *J Appl Physiol* (1985) 77: 2740-7, 1994.
- 502 24. McCabe C, Bennett M, Doughty N, MacKenzie Ross R, Sharples L, Pepke-Zaba
503 J. Patient-reported outcomes assessed by the CAMPHOR questionnaire predict
504 clinical deterioration in idiopathic pulmonary arterial hypertension and chronic
505 thromboembolic pulmonary hypertension. *Chest* 144: 522-30, 2013.
- 506 25. McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The
507 Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure
508 of health-related quality of life and quality of life for patients with pulmonary
509 hypertension. *Qual Life Res* 15: 103-15, 2006.
- 510 26. Mereles D, Ehlken N, Kreuzer S, Ghofrani S, Hoeper MM, Halank M, Meyer
511 FJ, Karger G, Buss J, Juenger J, Holzappel N, Opitz C, Winkler J, Herth FF,
512 Wilkens H, Katus HA, Olschewski H, Grünig E. Exercise and respiratory training
513 improve exercise capacity and quality of life in patients with severe chronic
514 pulmonary hypertension. *Circulation* 114: 1482-9, 2006.
- 515 27. Morris NR, Seale H, Harris J, Hall K, Lin AC, Kermeen F. Gas exchange
516 responses during 6-min walk test in patients with pulmonary arterial hypertension.
517 *Respirology* (Aug 16, 2016). doi: 10.1111/resp.12868.
- 518 28. Myers J, Gullestad L, Bellin D, Ross H, Vagelos R, Fowler M. Physical activity
519 patterns and exercise performance in cardiac transplant recipients. *J Cardiopulm*
520 *Rehabil* 23: 100-6, 2003.
- 521 29. Naeije R. Breathing more with weaker respiratory muscles in pulmonary arterial
522 hypertension. *Eur Respir J* 25:6–8, 2005.
- 523 30. Okumus G, Aslan GK, Arseven O, Ongen G, Issever H, Kıyan E. The role of an
524 activity monitor in the objective evaluation of patients with pulmonary
525 hypertension. *Clin Respir J* (May 5, 2016). doi: 10.1111/crj.12495.
- 526 31. Panagiotou M, Peacock AJ, Johnson MK. Respiratory and limb muscle
527 dysfunction in pulmonary arterial hypertension: a role for exercise training? *Pulm*
528 *Circ* 5: 424-34, 2015.
- 529 32. Panagiotou M, Vogiatzis I, Louvaris Z, Jayasekera G, MacKenzie A, Mcglinchey
530 N, Baker JS, Church AC, Peacock AJ, Johnson MK. Dynamic near-infrared
531 spectroscopy assessment as an important tool to explore pulmonary arterial
532 hypertension pathophysiology. *Eur Respir J*; 49: 1602161, 2017.
- 533 33. Panagiotou M, Vogiatzis I, Louvaris Z, Jayasekera G, MacKenzie A, Mcglinchey
534 N, Baker JS, Church AC, Peacock AJ, Johnson MK. Near infrared spectroscopy
535 for the assessment of peripheral tissue oxygenation in pulmonary arterial
536 hypertension. *Eur Respir J* 48: 1224-1227, 2016.
- 537 34. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R.
538 Characteristics of physical activities in daily life in chronic obstructive pulmonary
539 disease. *Am J Respir Crit Care Med* 171: 972-7, 2005.
- 540 35. Provencher S, Chemla D, Hervé P, Sitbon O, Humbert M, Simonneau G. Heart
541 rate responses during the 6-minute walk test in pulmonary arterial hypertension.
542 *Eur Respir J* 27: 114-20, 2006.

- 543 36. Pugh ME, Buchowski MS, Robbins IM, Newman JH, Hemnes AR. Physical
544 activity limitation as measured by accelerometry in pulmonary arterial
545 hypertension. *Chest* 142: 1391-8, 2012.
- 546 37. Rabinovich RA, Louvaris Z, Raste Y, Langer D, Van Remoortel H, Giavedoni S,
547 Burtin C, Regueiro EM, Vogiatzis I, Hopkinson NS, Polkey MI, Wilson FJ,
548 Macnee W, Westerterp KR, Troosters T; PROactive Consortium. Validity of
549 physical activity monitors during daily life in patients with COPD. *Eur Respir J*
550 42: 1205-15, 2013.
- 551 38. Roman A, Barbera JA, Castillo MJ, Muñoz R, Escribano P. Health-related quality
552 of life in a national cohort of patients with pulmonary arterial hypertension or
553 chronic thromboembolic pulmonary hypertension. *Arch Bronconeumol* 49: 181-8,
554 2013.
- 555 39. Saglam M, Vardar-Yagli N, Calik-Kutukcu E, Arikan H, Savci S, Inal-Ince D,
556 Akdogan A, Tokgozoglu L. Functional exercise capacity, physical activity, and
557 respiratory and peripheral muscle strength in pulmonary hypertension according
558 to disease severity. *J Phys Ther Sci* 27: 309-12, 2015.
- 559 40. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in
560 patients with primary pulmonary hypertension. *Circulation* 104: 429-35 2001.
- 561 41. Tolle J, Waxman A, Systrom D. Impaired systemic oxygen extraction at
562 maximum exercise in pulmonary hypertension. *Med Sci Sports Exerc* 40: 3-8,
563 2008.
- 564 42. Tonelli AR, Alnuaimat H, Li N, Carrie R, Mubarak KK. Value of impedance
565 cardiography in patients studied for pulmonary hypertension. *Lung*; 189: 369-75,
566 2011.
- 567 43. Tudor-Locke C, Craig CL, Thyfault JP, Spence JC. A step-defined sedentary
568 lifestyle index: <5000 steps/day. *Appl Physiol Nutr Metab* 38: 100-14, 2013.
- 569 44. Tung HH, Jan MS, Lin CY, Chen SC, Huang HC. Mediating role of daily
570 physical activity on quality of life in patients with heart failure. *J Cardiovasc*
571 *Nurs* 27: 16-23, 2012.
- 572 45. Ulrich S, Fischler M, Speich R, Bloch KE. Wrist actigraphy predicts outcome in
573 patients with pulmonary hypertension. *Respiration* 86: 45-51, 2013.
- 574 46. van Hees VT, van Lummel RC, Westerterp KR. Estimating activity-related
575 energy expenditure under sedentary conditions using a tri-axial seismic
576 accelerometer. *Obesity (Silver Spring)* 17: 1287-92, 2009.
- 577 47. Witham MD, Argo IS, Johnston DW, Struthers AD, McMurdo ME. Predictors of
578 exercise capacity and everyday activity in older heart failure patients. *Eur J Heart*
579 *Fail* 8: 203-7, 2006.
- 580 48. Yorke J, Corris P, Gaine S, Gibbs JS, Kiely DG, Harries C, Pollock V, Armstrong
581 I. emPHasis-10: development of a health-related quality of life measure in
582 pulmonary hypertension. *Eur Respir J* 43: 1106-13, 2014.